Fall / Winter 2019 | Category
One of the most promising targets in
Parkinson’s is LRRK2. People with mutations
in this gene are at higher risk of Parkinson’s.
Research suggests that even Parkinson’s
patients without a mutation may benefit from
drugs targeting LRRK2 and early trials are now
exploring this idea further. The first LRRK2
therapy, from San Francisco biotech Denali,
entered trials in 2017. Biogen has recently
announced plans to begin human studies of
their own and more are on the way. MJFF has
been active in supporting all LRRK2 trials, first
by addressing potential safety issues and then
through recruitment support.
“Living with Parkinson’s, I’m as ready as
anyone for the next breakthrough,” says Board
Chair Jeff Keefer.
Visit michaeljfox.org for the latest research
news from the Foundation and learn how you
can get involved in clinical studies.